Data on Medicare’s net prices for prescription drugs and other drug pricing metrics

Shinobu Suzuki, Rachel Schmidt, Kim Neuman, and Nancy Ray
October 7, 2021
Consolidated Appropriations Act, 2021, newly provides Commission with access to two sets of data

- Post-sale rebates and fees (direct and indirect remuneration (DIR) data) for Part D outpatient drugs
- Pricing data for provider-administered drugs under Part B and drugs covered under Medicaid
  - Average sales price (ASP)
  - Average manufacturer price (AMP)
  - Best price (BP)
- Data subject to disclosure limitations defined by statute
Gross drug prices at the pharmacy do not reflect post-sale rebates and pharmacy fees

Direct and indirect remuneration (DIR)
Sponsors report plan-level DIR to CMS retrospectively for each benefit year

- Any price concession to the sponsor or an intermediary that decreases a plan’s costs directly or indirectly
- Used to reconcile prospective plan payments with plan’s final costs of providing benefits
- DIR has grown from <10% of gross Part D spending in 2007 (~$5 billion) to >26% in 2019 ($48 billion)
- Two types of DIR reports
  - Summary report shows categories of DIR for each plan
  - Detailed report shows DIR at national drug code (NDC-11) level
Manufacturers report ASP data to CMS to establish Part B drug payment rates

- Drug manufacturers report ASP and utilization data to CMS at the 11-digit NDC-level
- Medicare generally pays 106% of ASP for Part B drugs
- Part B drug payment rates are set at the billing code level
  - CMS calculates the volume-weighted average ASP across all NDCs assigned to a billing code
- Payment rates are public, but NDC-level ASP data are not
- CAA, 2021, grants MedPAC access to NDC-level ASP data

Note: CAA (Consolidated Appropriations Act).
Manufacturers report AMP and BP data to CMS

- Manufacturers report NDC-level AMP and BP data to CMS for administration of Medicaid
  - States receive rebates on Medicaid-covered outpatient drugs using formulas that are based on AMP and/or BP
- AMP and BP data also have broader implications
  - For Part B drugs, if OIG finds ASP > AMP by at least 5%, CMS can substitute 103% AMP for 106% ASP
  - For providers that purchase outpatient drugs via the 340B program, the 340B ceiling price = AMP – Medicaid unit rebate amount
CAA, 2021’s limitations on disclosure

- Prohibits disclosure in a form that would reveal the identity of a specific manufacturer or wholesaler or the prices they charged

- For DIR data, it also prohibits revealing plan-level dollar amounts or identities of sources of price concessions
Plans for analysis using DIR data

- Initially focus on:
  - Validating the accuracy of the data
  - Understanding the limitations of its use in research (e.g., sponsors use different algorithm to allocate DIR across plans and/or NDCs)

- Potential Part D research topics:
  - Effects of competition on rebates
  - Relationship between rebates and point-of-sale prices
  - Effects of rebates on the accuracy of Part D’s risk adjustment
Plans for analysis of ASP and other data

- Initially focus on:
  - Data validation – replicate Part B drug payment rates
- Potential Part B research topics
  - Combined billing code policies
  - Variation in ASP within billing codes
  - Generic drug pricing and utilization dynamics
- Compare Part B and Part D net price growth for similar types of products
Next steps

- In April, we plan to come back to you with preliminary information about the pricing data, including their strengths and limitations.

- We would like your feedback on:
  - Analytical plans discussed in this presentation / mailing material
  - Relative priority among the research projects
  - Additional research ideas